{"id":"NCT04050865","sponsor":"Ocular Therapeutix, Inc.","briefTitle":"A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis","officialTitle":"CLN-0052, A Multi-Center, Randomized, Double-Masked, Vehicle Controlled Phase 3 Study Evaluation the Efficacy and Safety of OTX-DP for the Treatment of Allergic Conjunctivitis Using a Modified Conjunctival Allergen Challenge Model (Ora-CACÂ®)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-08-05","primaryCompletion":"2020-02-28","completion":"2020-02-28","firstPosted":"2019-08-08","resultsPosted":"2021-10-07","lastUpdate":"2021-10-07"},"enrollment":96,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Allergic Conjunctivitis"],"interventions":[{"type":"DRUG","name":"Dexamethasone, 0.4mg","otherNames":["OTX-DP"]},{"type":"DEVICE","name":"Placebo plug with no drug","otherNames":[]}],"arms":[{"label":"OTX-DP","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of the study is to evaluate the efficacy and safety of OTX-DP as a dexamethasone ophthalmic insert when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of allergic conjunctivitis.","primaryOutcome":{"measure":"Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6 (7 Days Post-insertion)","timeFrame":"3 minutes","effectByArm":[{"arm":"OTX-DP","deltaMin":1.8,"sd":null},{"arm":"Placebo","deltaMin":2.69,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":6,"countries":["United States"]},"refs":{"pmids":["39328900"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":48},"commonTop":["Treatment Emergent Adverse Events"]}}